title: JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kröger
authors.forename: Haefaa
authors.initials: H
authors.lastname: Alchalby
authors.forename: Evgeny
authors.initials: E
authors.lastname: Klyuchnikov
authors.forename: Anita
authors.initials: A
authors.lastname: Badbaran
authors.forename: York
authors.initials: Y
authors.lastname: Hildebrandt
authors.forename: Francis
authors.initials: F
authors.lastname: Ayuk
authors.forename: Ulrike
authors.initials: U
authors.lastname: Bacher
authors.forename: Oliver
authors.initials: O
authors.lastname: Bock
authors.forename: Michael
authors.initials: M
authors.lastname: Kvasnicka
authors.forename: Boris
authors.initials: B
authors.lastname: Fehse
authors.forename: Axel
authors.initials: A
authors.lastname: Zander
mesh_terms: D000328:Adult; D020350:Graft vs Tumor Effect; D006801:Humans; D016219:Immunotherapy, Adoptive; D053614:Janus Kinase 2 / Q000235:genetics*; D008875:Middle Aged; D017354:Point Mutation; D055728:Primary Myelofibrosis / Q000503:physiopathology* / Q000628:therapy*; D012074:Remission Induction; D016879:Salvage Therapy; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2